Development of NvA-011 for topical application in Dystrophic Epidermolysis Bullosa
| Biotech website | vikingglobal.com/portfolio/nova-anchora/ |
| Investment details | $225,000 (£167,100) |
| Start date | December 2024 |
| Research area | Protein therapy |
| Aim | Quality of life change |
| EB sub-type | Dystrophic EB |
| Investment status | Current |
Investment summary
Nova Anchora’s lead product in development, NvA-011, a recombinant version of “genetically correct” collagen VII, is designed to be applied topically as a gel and replace collagen VII in the skin of individuals with dystrophic epidermolysis bullosa (DEB).
This investment, alongside other investors, will support IND-enabling activities, such as completion of toxicology studies and finalising manufacturing processes in readiness for clinical trials.